Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal activates CYLD. 1 / 1

| 1

➶

reach

"Given that CYLD is a well characterized NF-kappaB transcriptional target, and in keeping with results obtained from DLD1, HCT116 and COS7 cells (XREF_SUPPLEMENTARY), there are low expression levels of endogenous CYLD and contrary to RANKL stimulated conditions, CYLD could not be upregulated by MG132 that is largely due to the inhibitory effects of MG132 towards NF-kappaB signaling."

24961988

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...